VERAXA Biotech Enters a Business Combination Agreement with Voyager Acquisition Corp to Develop Cancer Therapies
Shots:
- VERAXA to reverse merge with Voyager, where the combined entity- "VERAXA Biotech” will be listed on Nasdaq under VERX ticker; closing expected in Q4’25
- As per the deal, VERAXA will have access to ~$253M cash from Voyager’s trust at closing & contribute ~$1.3B in equity for ~130M shares, with all shareholders rolling over 100% equity, valuing the combined entity at ~$1.64B (at $10/share). VERAXA is also raising a crossover round to fund operations for 2yrs., excl. partnerships, which is expected to close before merger
- VERAXA’s pipeline contains 9 programs incl. VX-A901 in P-I for leukemia & aims to advance 3 clinical programs & expand licensed assets by 2029
Ref: Globenewswire | Image: VERAXA & Voyager
Related News:- Alumis and ACELYRIN Revise Merger Agreement, Boosting ACELYRIN Stake
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
